Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$13.41M+169.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Matthew W. Foehr
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 89
- Beta
- 1.05
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 13.11
Financials
Revenue
$13.41M+169.0%Net Income
$-5.86MEBITDA
$-6.21MFree Cash Flow
$2.57M+65.6%EPS (diluted)
$-0.05Shares Outstanding (diluted)
128.79M+12.2%Operating Expenses
$16.24MCash & Debt
$51.99MRevenue by Segment (annual)
$8.14MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $18.67M | $-64.78M | $-0.57 |
| 2024 | $26.39M | $-62.03M | $-0.61 |
| 2023 | $34.16M | $-50.62M | $-0.51 |
| 2022 | $59.08M | $-22.33M | $-0.26 |
| 2021 | $34.75M | $-27.04M | $-0.24 |
| 2020 | $23.27M | $-17.56M | $-0.15 |
| 2019 | $18.32M | $-13.59M | $-0.12 |
Valuation
OABIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-80.00%Social Signal Score
Mentions (3)
- Newsseekingalpha.com·49d ago·Negative
…is Early-Stage Biotech OmniAb is transitioning from early-stage biotech to a scalable platform, driven by milestone-rich partnerships like the recent Eli Lilly deal. OABI's 110 partners and 425 programs are generating higher, more predictable milestone revenues, with $340M in clinical-stage milestone potential and a $3B+ total milestone pool. The Lilly collaboration validates OABI's technology, offers high-margin, capital-light economics, and has directly improved 2026 cash guidance to $49–$53M.
View source ↗ - Newsbusinesswire.com·50d ago·Neutral
OmniAb Raises 2026 Financial Guidance EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today raised its 2026 cash and cash equivalents financial guidance following recent technology licensing activity. “Recent business development and licensing activity has enabled us to again raise our 2026 financial guidance and significantly increase our cash outlo…
View source ↗ - Newsbusinesswire.com·50d ago·Neutral
OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced a global collaboration and license agreement with Eli Lilly and Company (Lilly) for a new ion channel program. The collaboration leverages OmniAb's technology platform and experti…
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $-0.12 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.05 vs $-0.12beat
- Thu, May 7$-0.06 vs $-0.10beat
- Wed, Mar 4$-0.11 vs $-0.08miss
- Tue, Nov 4$-0.14 vs $-0.14miss
- Wed, Aug 6$-0.15 vs $-0.14miss
- Thu, May 8$-0.17 vs $-0.17beat
Estimates and results for OABI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by OABI officers and directors.
- Bought
- $108k
- Sold
- $283k
2 trades
12 trades
- Foehr Matthew Wsold
- Gustafson Kurt Asold
- Berkman Charles Ssold
- Berkman Charles Ssold
- Gustafson Kurt Asold
- Foehr Matthew Wsold
- Foehr Matthew Wsold
- Gustafson Kurt Asold
86 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in OABI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.